MedTrace Logo

Pluvicto Real-world Investigation in Survival in Metastatic CRPC

NCT07697989 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1085

Last updated 2026-07-22

No results posted yet for this study

Summary

This study aims to evaluate the various aspects of treatment effectiveness of \[177Lu\]Lu-PSMA-617 (Pluvicto) in mCRPC patients in both pre- and post-taxane settings. The study will be conducted using real-world data sources from the United States (US) and Germany.

Conditions

  • Prostatic Neoplasms, Castration-Resistant
  • Neoplasm Metastasis

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-15
Primary Completion
2027-01-31
Completion
2027-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07697989 on ClinicalTrials.gov